TORONTO, Dec. 9, 2021 /CNW/ - Khiron Life Sciences
Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, announced today
its CEO, Alvaro Torres will be
participating in the Lytham Partners Winter 2021 Investor
Conference taking place from December 13-16,
2021. During the event, the company will be participating in
a webcasted Fireside Chat discussing its vision for 2022 and
conducting 1x1 virtual investor meetings.
The webcasted Fireside Chat will be available for viewing at
11:00am ET on Monday, December 13,
2021 on the Company's website at
https://investors.khiron.ca/investor-information or
https://wsw.com/webcast/lytham3/khrn/2039430. The webcast will also
be available for replay following the event.
To arrange a 1x1 meeting with management, please contact Lytham
Partners at 1x1@lythampartners.com or register at
www.lythampartners.com/winter2021invreg.
Recent Company Highlights:
- Opened first clinic in Europe
with ZereniaTM Clinics, London, UK
- Continuing to develop real-world evidence from
cannabinoid-based treatments to improve patient treatment and
physician education, and conduct pharmacoeconomic studies,
including the presentation of the Company's first medical cannabis
study with more than 1,400 patients
- Completing its first medical cannabis sale in Brazil and continuing establishing key
components for Khiron first ZereniaTM clinic in the
country, increasing patient access to affordable, high-quality
medical cannabis products
- Filled over 50,000 medical cannabis prescriptions in
Latin America since beginning of
operations
- Q3 2021 revenue increased 83% YoY to $3.5 million compared to the previous year
- Medical cannabis revenues increased 46% sequentially to
$1.2 million
- Continued strong gross margins for medical cannabis segment at
89%
About Khiron Life Sciences Corp.
Khiron is a leading
vertically integrated international medical cannabis company with
core operations in Latin America and Europe.
Leveraging wholly owned medical health clinics and proprietary
telemedicine platforms, Khiron combines a patient-oriented
approach, physician education programs, scientific expertise,
product innovation, and agricultural infrastructure to drive
prescriptions and brand loyalty with patients worldwide. The
Company has a sales presence
in Colombia, Peru, Germany, UK,
and Brazil and is positioned to commence sales
in Mexico . The Company is led by Co-founder and Chief
Executive Officer, Alvaro Torres, together with an experienced
and diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Linkedin
at
https://www.linkedin.com/company/khiron-life-sciences-corp/
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile
at www.sedar.com . The forward-looking information
contained in this press release is expressly qualified by this
cautionary statement and is made as of the date hereof. Khiron
disclaims any intention and has no obligation or responsibility,
except as required by law, to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/khiron-to-participate-in-the-lytham-partners-winter-2021-investor-conference-301441176.html
SOURCE Khiron Life Sciences Corp.